FDA Siding Against Eteplirsen Approval Not Entirely Surprising; Baird Affirms Sarepta (SRPT) at 'Outperform'
Tweet Send to a Friend
Baird reaffirms Sarepta Therapeutics (Nasdaq: SRPT) wtih an Outperform rating and $47 price target after the FDA posted eteplirsen briefing ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
